Abstract
A series of novel arylantimony ferrocenylcarboxylate derivatives with the formulae [C 5H 5FeC 5H 4C(CH 3)CHCOO] 2SbAr 3 and [4-(C 5H 5FeC 5H 4)C 6H 4COO] 2SbAr 3 (Ar=C 6H 5, 4-CH 3C 6H 4, 4-ClC 6H 4, 4-FC 6H 4) were synthesized and characterized by elemental analysis, IR and 1H NMR. The crystal structures of [C 5H 5FeC 5H 4C(CH 3)CHCOO] 2Sb(C 6H 4F-4) 3 and [4-(C 5H 5FeC 5H 4)C 6H 4COO] 2Sb(C 6H 4F-4) 3 were determined by X-ray diffraction. The two sets of crystal X-ray data show that the antimony atom of the former has a special six-coordinate geometry while that of the latter has a general five-coordinate geometry. Three human neoplastic cell lines (HCT-8, Bel-7402 and KB) were used to screen these compounds. The results indicate that [C 5H 5FeC 5H 4C(CH 3)CHCO 2] 2Sb(C 6H 4Cl-4) 3 and [C 5H 5FeC 5H 4C(CH 3)CHCO 2] 2Sb(C 6H 4F-4) 3 at 5 μM show relatively good in vitro antitumor activities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
